ArticleMedicine2026
Elevated C-reactive protein and failure to achieve remission in pediatric lupus nephritis: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lupus nephritis (LN) is a serious complication that adversely affects the prognosis of children with systemic lupus erythematosus. However, short-term prognostic indicators for LN in this population remain unclear. This retrospective cohort study aimed to identify factors associated with treatment remission in Chinese children with LN, with a focus on inflammatory markers. We included 72 children aged 0 to 18 years diagnosed with LN at our center between January 2022 and December 2024. Partial remission was defined as a ≥50% reduction from baseline in proteinuria and to an absolute value of <3.0 g/g (300 mg/mmol), measured as the protein-to-creatinine ratio from a 24-hour urine collection, accompanied by stabilization or improvement in kidney function (estimated glomerular filtration rate, eGFR, within ±10% to 15% of baseline). The non-remission group comprised patients who failed to meet the above partial remission criteria within the 8 to 24 week follow-up period. Both univariate and multivariate Cox regression analyses revealed that elevated C-reactive protein (CRP) levels were significantly associated with failure to achieve remission (univariate hazard ratio 1.067, 95% CI: 1.011-1.126, P = .019; multivariate hazard ratio 1.075, 95% CI: 1.019-1.134, P = .008). A nomogram incorporating CRP demonstrated moderate discriminatory capacity for remission status at 24 weeks (AUC = 0.739). These findings indicate that baseline CRP is an independent risk factor for short-term remission failure in pediatric LN, suggesting that its monitoring may be beneficial for guiding clinical interventions. In conclusion, elevated CRP is an independent risk factor for short-term remission failure, and its monitoring may be beneficial for assessing treatment outcome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.